Therapy for unresectable hepatocellular carcinoma: Review of the randomized clinical trials - II: Systemic and local non-embolization-based therapies in unresectable and advance hepatocellular carcinoma

Anti-Cancer Drugs

Volumn 15, Issue 5, 2004, Pages 439-452

  Schwartz, Jonathan D ^a   Beutler, Andreas S ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Antineoplastic agents; Drug therapy; Embolization; Hepatocellular carcinoma; Liver neoplasms; Randomized controlled trials; Therapeutic

Indexed keywords

ACIVICIN; ALPHA INTERFERON; AMSACRINE; CARBOQUONE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ESTROGEN RECEPTOR; ETOPOSIDE; FLUOROPYRIMIDINE; FLUOROURACIL; IODINATED POPPYSEED OIL; MEGESTROL; METHOTREXATE; MITOMYCIN; MITOXANTRONE; NOLATREXED; OCTREOTIDE; PICIBANIL; PRAVASTATIN; SEMUSTINE; STREPTOZOCIN; TAMOXIFEN; TEGAFUR; TENIPOSIDE; UNINDEXED DRUG; URACIL; VINCRISTINE; ZINOSTATIN;

ALOPECIA; ANEURYSM; ARTIFICIAL EMBOLISM; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CHEMOEMBOLIZATION; CLINICAL TRIAL; COLON POUCH; CYTOPENIA; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FLU LIKE SYNDROME; GASTROINTESTINAL INFECTION; GASTROINTESTINAL TOXICITY; HEPATIC ARTERY; HOT FLUSH; HUMAN; INTESTINE FISTULA; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER FUNCTION; MEDLINE; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; PRURITUS; REVIEW; THROMBOCYTOPENIA; THROMBOPHLEBITIS; VOMITING;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; CARCINOMA, HEPATOCELLULAR; EMBOLIZATION, THERAPEUTIC; HEPATIC ARTERY; IMMUNOTHERAPY; INFUSIONS, INTRA-ARTERIAL; INFUSIONS, INTRAVENOUS; IODINE RADIOISOTOPES; IODIZED OIL; LIVER NEOPLASMS; RADIOPHARMACEUTICALS; RANDOMIZED CONTROLLED TRIALS; TAMOXIFEN;

EID: 2942601262     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000131140.12228.bb     Document Type: Review

References (68)

1. Llovet J, Bustamente J, Castells A, Vilana R, Ayuso C, Sala M, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rational for the design and evaluation of therapeutic trials. Hepatology 1999; 29:62-67.
2. Schwartz JD, Lehrer D, Mandeli J, Goldenberg A, Sung M, Volm M. Thalidomide in hepatocellular cancer (HCC) with optional interferon-alpha upon progression. Proc Am Soc Clin Oncol 2003; 22:A1210 (1301).
3. Okada S. Chemotherapy in hepatocellular carcinoma. Hepatogastroenterology 1998; 45(suppl 3):1259-1263.
4. Geschwind JF, Ramsey DE, Choti MA, Thuluvath PJ, Huncharck MS. Chemoembolization of hepatocellular carcinoma: results of a metaanalysis. Am J Clin Oncol 2003; 26:344-349.
5. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37:429-442.
6. Simonetti RG, Liberati A, Angiolini C, Pagliaro L. Treatment of hepatocellular carcinoma: a systemic review of randomized controlled trials. Ann Oncol 1997; 8:117-136.
7. Trevisani F, De Notariis S, Rossi C, Bernardi M. Randomized controlled trials on chemoembolization in hepatocellular carcinoma: is there room for new studies? J Clin Gastroenterol 2001; 5:383-389.
8. Schwartz JD, Schwartz M, Mandeli J, Sung M. Neoadjuvant and adjuvant therapy for resectabte hepatocellular carcinoma: review of the randomised clinical trials. Lancet Oncol 2002; 3:593-603.
9. Lai CL, Wu PC, Chan GC, Lok AS, Lin HJ. Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer 1988; 62:479-483.
10. Ishikawa T, Ichida T, Sugitani S, Tsuboi Y, Genda T, Sugahara S, et al. Improved survival with oral administration of enteric-coated tegafur/uracil for advanced stage IV-A hepatocellular carcinoma. J Gastroenterol Hepatol 2001; 16:452-459.
11. Chung YH, Song IH, Song BC, Lee GC, Koh MS, Yoon HK, et al. Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon-alpha for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis. Cancer 2000; 88:1986-1991.
12. Madden MV, Krige JE, Bailey S, Beningfield SJ, Geddes C, Werner ID, et al. Randomised trial of targeted chemotherapy with lipiodol and 5-epidoxorubicin compared with symptomatic treatment for hepatoma. Gut 1993; 34:1598-1600.
13. Falkson G, Moertel CG, Lavin P, Pretorius FJ, Carbone PP. Chemotherapy studies in primary liver cancer: a prospective randomized clinical trial. Cancer 1978; 42:2149-2156.
14. Falkson G, MacIntyre JM, Moertel CG, Johnson LA, Scherman RC. Primary liver cancer: an Eastern Cooperative Oncology Group Trial. Cancer 1984; 54:970-977.
15. Choi TK, Lee NW, Wong J. Chemotherapy for advanced hepatocellular carcinoma. Adriamycin versus quadruple chemotherapy. Cancer 1984; 53:401-405.
16. Melia WM, Johnson PJ, Williams R. Induction of remission in hepatocellular carcinoma. A comparison of VP 16 with adriamycin. Cancer 1983; 51:206-210.
17. Falkson G, Ryan LM, Johnson LA, Simson IW, Coetzer BJ, Carbone PP, et al. A random phase II study of mitoxantrone and cisplatin in patients with hepatocellular carcinoma. An ECOG study. Cancer 1987; 60:2141-2145.
18. Falkson G, MacIntyre JM, Schutt AJ, Coetzer B, Johnson LA, Simson IW, et al. Neocarzinostatin versus m-AMSA or doxorubicin in hepatocellular carcinoma. J Clin Oncol 1984; 2:581-584.
19. Bezwoda WR, Weaving A, Kew M, Derman DP. Combination chemotherapy of hepatocellular cancer. Comparison of adriamycin + VM 26 + 5-fluorouracil with mAMSA + VM 26 + 5-fluorouracil. Oncology 1987; 44:207-209.
20. Sakata Y, Komatsu Y, Takagi S, Saitoh S, Itoh T, Suzuki H, et al. Randomized controlled study of mitomycin C/carboquone/5-fluorouracil/OK-432 (MQ-F-OK) therapy and mitomycin C/5-fluorouracil/doxorubicin (FAM) therapy against advanced liver cancer. Cancer Chemother Pharmacol 1989; 23(suppl):S9-S12.
21. Falkson G, Cnaan A, Simson IW, Dayal Y, Falkson H, Smith TJ, et al. A randomized phase II study of acivicin and 4′-deoxydoxorubicin in patients with hepatocellular carcinoma in an Eastern Cooperative Oncology Group study. Am J Clin Oncol 1990; 13:510-515.
22. Kiire CF, Gombe-Mbalawa C, Tsega E, Luande J, Menenses LV, Okoth J, et al. Multicentre study of the treatment of primary liver cancer in Africa with two anthracycline drugs. Cent Afr J Med 1992; 38:428-431.
23. Mok TS, Leung TW, Lee SD, Chao Y, Chan AT, Huang A, et al. A multi-centre randomized phase II study of nolatrexed versus doxorubicin in treatment of Chinese patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 1999; 44:307-311.
24. Kajanti M, Pyrhonen S, Mantyla M, Rissanen P. Intra-arterial and intravenous use of 4′ epidoxorubicin combined with 5-fluorouracil in primary hepatocellular carcinoma. A randomized comparison. Am J Clin Oncol 1992; 15:37-40.
25. Tzoracoleftherakis EE, Spiliotis JD, Kyriakopoulou T, Kakkos SK. Intra-arterial versus systemic chemotherapy for non-operable hepatocellular carcinoma. Hepatogastroenterology 1999; 46:1122-1125.
26. Yoshikawa M, Saisho H, Ebara M, Iijima T, Iwama S, Endo F, et al. A randomized trial of intrahepatic arterial infusion of 4′-epidoxorubicin with Lipiodol versus 4′-epidoxorubicin alone in the treatment of hepatocellular carcinoma. Cancer Chemother Pharmacol 1994; 33(suppl):S149-S152.
27. Ikeda K, Saitoh S, Koida I, Tsubota A, Arase Y, Chayama K, et al. A prospective randomized evaluation of a compound of tegafur and uracil as an adjuvant chemotherapy for hepatocellular carcinoma treated with transcatheter arterial chemoembolization. Am J Clin Oncol 1995; 18:204-210.
28. Ikeda K, Saitoh S, Suzuki Y, Koida I, Tsubota A, Kobayashi M, et al. A prospective randomized administration of 5′-deoxy-5-fluorouridine as adjuvant chemotherapy for hepatocellular carcinoma treated with transcatheter arterial chemoembolization. Am J Clin Oncol 1997; 20:202-208.
29. Kawata S, Yamasaki E, Nagase T, Inui Y, Ito N, Matsuda Y, et al. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br J Cancer 2001; 84:886-891.
30. Agarwal B, Rao CV, Bhendwal S, Ramey WR, Shirin H, Reddy BS, et al. Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemopreventive effects of sulindac. Gastroenterology 1999; 117:838-847.
31. Reichle A, Bross K, Vogt T, Bataille F, Wild P, Wodzynski P et al. Pioglitazone and rofecoxib combined with angiostatic scheduling of chemotherapy in far advanced malignancies. Proc Am Soc Clin Oncol 2002; 21:A19.
32. Verhuel HMW, Panigrahy D, Yuan J, D'Amato RJ. Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumour growth in rabbits. Br J Cancer 1999; 79:114-118.
33. Rumi MAK, Sato H, Ishihara S, Kawashima K, Hamamoto S, Kazumori H, et al. Peroxisome proliferator-activated receptor gamma ligand-induced growth inhibition of human hepatocellular carcinoma. Br J Cancer 2001; 84:1640-1647.
34. Lai CL, Wu PC, Lok AS, Lin HJ, Ngan H, Lau JY, et al. Recombinant alpha 2 interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: a prospective randomised trial. Br J Cancer 1989; 60:928-933.
35. Llovet JM, Sala M, Castells L, Suarez Y, Vilana R, Bianchi L, et al. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology 2000; 31:54-58.
36. Lai CL, Lau JY, Wu PC, Ngan H, Chung HT, Mitchell SJ, et al. Recombinant interferon-alpha in inoperable hepatocellular carcinoma: a randomized controlled trial. Hepatology 1993; 17:389-394.
37. Falkson G, Lipsitz S, Borden E, Simson I, Haller D. Hepatocellular carcinoma. An ECOG randomized phase II study of beta-interferon and menogaril. Am J Clin Oncol 1995; 18:287-292.
38. Miyaguchi S, Watanabe T, Takahashi H, Nakamura M, Saito H, Ishii H. Interferon therapy for hepatocellular carcinoma in patients with low HCV-RNA levels. Hepatogastroenterology 2002; 49:724-729.
39. Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of hepatocarcinogenesis by interferon therapy. Ann Intern Med 1999; 131:174-181.
40. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S. Randomised trial of effects of interferon alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346:1051-1055.
41. Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Kinoshita H. Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy. Br J Surg 2002; 89:418-422.
42. Shiratori Y, Shiina S, Teratani T, Imamura M, Obi S, Sato S, et al. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med 2003; 138:299-306.
43. Raoul JL, Guyader D, Bretagne JF, Duvauferrier R, Bourguet P, Bekhechi D, et al. Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: intra-arterial iodine-131-iodized oil versus medical support. J Nucl Med 1994; 35:1782-1787.
44. 131I antiferritin: an RTOG study. Int J Radiat Oncol Biol Phys 1991; 20:953-963.
45. 131iodine-Lipiodol radiotherapy in the treatment of unresectable hepatocellular carcinoma. Cancer 1995; 76:2202-2210.
46. 131I-labeled-iodized oil in the treatment of hepatocellular carcinoma. Hepatology 1997; 26:1156-1161.
47. Brans B, Van Laere K, Gemmel F, Defreyne L, Vanlangenhove P, Troisi R, et al. Combining iodine-131 lipiodol as therapy with low-dose cisplatin as a radiosensitiser: preliminary results in hepatocellular carcinoma. Eur J Nucl Med 2002; 29:928-932.
48. Lau WY, Leung TW, Ho SK, Chan M, Machin D, Lau J, et al. Adjuvant intraarterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial. Lancet 1999; 353:797-801.
49. Pocock S, White I. Trials stopped early: too good to be true? Lancet N Am Ed. 1999; 353:943-944.
50. Farinati F, Salvagnini M, de Maria N, Fornasiero A, Chiaramonte M, Rossaro L, et al. Unresectable hepatocellular carcinoma: a prospective controlled trial with tamoxifen. J Hepatol 1990; 11:297-301.
51. Farinati F, De Maria N, Fornasiero A, Salvagnini M, Fagiuoli S, Chiaramonte M, et al. Prospective controlled trial with antiestrogen drug tamoxifen in patients with unresectable hepatocellular carcinoma. Dig Dis Sci 1992; 37:659-662.
52. Martinez Cerezo FJ, Tomas A, Donoso L, Enriquez J, Guarner C, Balanzo J, et al. Controlled trial of tamoxifen in patients with advanced hepatocellular carcinoma. J Hepatol 1994; 20:702-706.
53. Elba S, Giannuzzi V, Misciagna G, Manghisi OG. Randomized controlled trial of tamoxifen versus placebo in inoperable hepatocellular carcinoma. Ital J Gastroenterol 1994; 26:66-68.
54. Manesis EK, Giannoulis G, Zoumboulis P, Vafiadou I, Hadziyannis SJ. Treatment of hepatocellular carcinoma with combined suppression and inhibition of sex hormones: a randomized, controlled trial. Hepatology 1995; 21:1535-1542.
55. CLIP Group. Tamoxifen in treatment of hepatocellular carcinoma: a randomised controlled trial. CLIP Group (Cancer of the Liver Italian Programme). Lancet 1998; 352:17-20.
56. Castells A, Bruix J, Bru C, Ayuso C, Roca M, Boix L, et al. Treatment of hepatocellular carcinoma with tamoxifen: a double-blind placebo-controlled trial in 120 patients. Gastroenterology 1995; 109:917-922.
57. Riestra S, Rodriguez M, Delgado M, Suarez A, Gonzalez N, de la Mata M, et al. Tamoxifen does not improve survival of patients with advanced hepatocellular carcinoma. J Clin Gastroenterol 1998; 26:200-203.
58. Chow PKH, Tai BC, Tan CK, Machin D, Win KM, Johnson P. High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: a multicenter randomized controlled trial. Hepatology 2002; 36:1221-1226.
59. Liu CL, Fan ST, Ng IO, Lo CM, Poon RT, Wong J. Treatment of advanced hepatocellular carcinoma with tamoxifen and the correlation with expression of hormone receptors: a prospective randomized study. Am J Gastroenterol 2000; 95:218-222.
60. Melia WM, Johnson PJ, Williams R. Controlled clinical trial of doxorubicin and tamoxifen versus doxorubicin alone in hepatocellular carcinoma. Cancer Treat Rep 1987; 71:1213-1216.
61. Uchino J, Une Y, Sato Y, Gondo H, Nakajima Y, Sato N. Chemohormonal therapy of unresectable hepatocellular carcinoma. Am J Clin Oncol 1993; 16:206-209.
62. Grimaldi C, Bleiberg H, Gay F, Messner M, Rougier P, Kok TC, et al. Evaluation of antiandrogen therapy in unresectable hepatocellular carcinoma: results of a European Organization for Research and Treatment of Cancer multicentric double-blind trial. J Clin Oncol 1998; 16:411-417.
63. Villa E, Ferretti I, Grottola A, Buttafoco P, Buono MG, Giannini F, et al. Hormonal therapy with megestrol in inoperable hepatocellular carcinoma characterized by variant oestrogen receptors. Br J Cancer 2001; 84:881-885.
64. Villa E, Colantoni A, Camma C, Grottola A, Buttafoco P, Gelmini R, et al. Estrogen receptor classification for hepatocellular carcinoma: comparison with clinical staging systems. J Clin Oncol 2003; 21:441-446.
65. Kouroumalis E, Skordilis P, Thermos K, Vasilaki A, Moschandrea J, Manousos ON. Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study. Gut 1998; 42:442-447.
66. Yuen MF, Poon RT, Lai CL, Fan ST, Lo CM, Wong KW, et al. A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma. Hepatology 2002; 36:687-691.
67. Carr BI, Amesur N, Zajko A, McCook B, Torok F, Geller M, et al. Safety and efficacy of hepatic artery 90-Y microspheres in unresectable hepatocellular carcinoma. Proc Am Soc Clin Oncol 2003; 22:1046A.
68. Poon RT, Ng IO, Lau C, Yu WC, Yang CF, Fan ST, et al. Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma: a prospective study. J Clin Oncol 2002; 21:1775-1785.